Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D. Founded in 1989, Vertex’s rollercoaster story is most iconically characterized by the rise and fall of Incivek, a hepatitis C drug that reached $1 billion in sales faster than any before it, only to be withdrawn from the market just three years afte ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors. There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity. However, Vertex Pharmaceuticals (VRTX 0.91%), a drugmaker with a monopoly in the cystic fibrosis (CF) market, hasn't done that -- quite the contrary. Since it launched its first CF product some 12 years ago, the biotech hasn ...

For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharma ...

Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2024 adjusted earnings per share of $4.76, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 56% year over year, driven by higher product revenues, lower costs and a lower tax rate in the quarter. The company reported total revenues of $2.69 billion, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of $2.56 billion. Total revenues rose 13% year over year, primarily driven by hig ...

财务数据和关键指标变化 - 第一季度收入同比增长13%至27亿美元,其中美国市场增长8%,海外市场增长21% [51] - 第一季度非GAAP营业利润同比增长48%至13亿美元,主要受益于收入增长和研发费用下降 [53][54] - 第一季度非GAAP税率为17.4%,低于上年同期的21.3% [53] - 第一季度非GAAP每股收益为4.76美元,高于上年同期的3.05美元 [53] - 公司现金及投资余额为146亿美元,将用于收购Alpine Immune Sciences [55] 各条业务线数据和关键指标变化 囊性纤维化业务 - 美国市场TRIKAFTA销售持续强劲,包括2-5岁患者群体 [33] - 欧洲市场KAFTRIO销售增长,包括2-5岁患者群体 [33] - 公司计划在2024年下半年推出新的vanzacaftor三联疗法,预计将为现有TRIKAFTA患者带来更好的疗效 [34][35] - 公司正在推进VX-522 mRNA疗法的临床开发,针对无法从CFTR调节剂中获益的5000多名囊性纤维化患者 [18] 镰状细胞病和地中海贫血业务 - CASGEVY在美国、欧洲和中东地区的发售取得良好进展,已有25个授权治疗中心启动,并有5名患者完成细胞采集 [37][38][39][40] - 公司与当地医疗机构合作,在沙特阿拉伯和巴林实现了CASGEVY的报销,预计这一地区的潜在患者群体超过23,000人 [41][42] 急性疼痛业务 - 公司正在推进VX-548在急性疼痛适应症的申报工作,已完成部分模块提交,预计本季度完成全部提交 [19] - 公司正在启动VX-993静脉给药剂型的I期临床试验,并计划在今年下半年启动口服制剂的II期临床试验 [20] - 公司正在与医院管理层、医生等各方利益相关方就VX-548的使用进行沟通,并关注相关政策法规的变化 [44][45][46][47][48][49] 公司战略和发展方向 - 公司将继续推进囊性纤维化、镰状细胞病和地中海贫血等核心业务的发展,并通过新产品上市实现进一步多元化 [49] - 公司宣布收购Alpine Immune Sciences,将获得其I期就绪的IgA肾病候选药物povetacicept,预计将于2027年获批上市并在2028年开始为公司贡献收入 [10][11][28][29][55][58] - 公司正在推进I/II期肌肉营养不良1型、I/II期多囊肾病等新适应症的临床开发 [10] - 公司将继续加大研发投入,推进包括VX-880 I型糖尿病、VX-264免疫逃逸等在内的中后期管线项目 [25][26][27] 管理层对经营环境和未来前景的评论 - 公司对囊性纤维化业务的未来发展前景保持乐观,将继续推动更多年龄段和地区的患者覆盖 [33][34] - 公司对CASGEVY在全球范围内的商业化前景充满信心,正在与各方利益相关方密切合作 [37][38][39][40][41][42] - 公司认为VX-548在急性疼痛领域具有良好的疗效和安全性优势,有望成为一款具有变革性的产品 [43][44][45][46][47][48][49] - 公司对收购Alpine获得的povetacicept在IgA肾病等适应症的潜力充满信心,预计将于2027年获批上市 [28][29][55][58] 问答环节重要的提问和回答 问题1 **Geoff Meacham提问** 公司是否会在vanzacaftor三联疗法的标签上强调其对汗液氯化物水平的改善效果? [64] **Reshma Kewalramani回答** 公司历来都会在CFTR调节剂的标签上体现汗液氯化物水平的数据,预计vanzacaftor三联疗法也会如此。具体标签内容还需与监管部门进一步沟通确定。[65] 问题2 **Jessica Fye提问** 公司是否考虑与商业合作伙伴共同开发针对肌肉骨骼疼痛的NaV1.8或NaV1.7抑制剂? [71] **Reshma Kewalramani回答** 公司计划自主开发和商业化急性疼痛和神经病理性疼痛适应症,但对于肌肉骨骼疼痛,公司会考虑与商业合作伙伴共同开发,因为这需要面向初级医疗市场。公司会分步推进,先专注于急性和神经病理性疼痛,再考虑肌肉骨骼疼痛。[72] 问题3 **Philip Nadeau提问** 公司是否预期VX-548在急性疼痛适应症上需要先经过普通阿片类药物的治疗才能使用? [93][94] **Stuart Arbuckle回答** 公司不希望看到这种情况发生。我们认为没有理由要求患者先使用存在成瘾风险的阿片类药物,而不是使用具有良好疗效和安全性的VX-548。公司会继续与各方利益相关方沟通,希望消除这种障碍。[95][96][97]

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.10%. A quarter ago, it was expected that this drugmaker would post earnings of $4.10 per share when it actually produced earnings of $4.20, delivering a surprise of 2.44%. Over the last four quarters, th ...

Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — —Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to-severe acute pain and on track to complete this quarter — — Entered into agreement to acquire Alpine Immune Sci ...

Wall Street analysts expect Vertex Pharmaceuticals (VRTX) to post quarterly earnings of $4.10 per share in its upcoming report, which indicates a year-over-year increase of 34.4%. Revenues are expected to be $2.56 billion, up 7.8% from the year-ago quarter. The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Bef ...